Related Experiment Video
Updated: Jun 21, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Safety of intravenous infusion of doripenem
Rebecca Redman1, Thomas M File
1Anti-Infectives Clinical Development, Johnson & Johnson Pharmaceutical Research & Development, 6500 Paseo Padre Pkwy., Fremont, CA 94555, USA. rredman@its.jnj.com
Abstract:
Carbapenems remain a mainstay for the empirical treatment of serious nosocomial infection. Although the tolerance and safety profile of the carbapenems as a class is favorable, the primary safety concern is the potential for treatment-emergent seizures. In preclinical testing, doripenem, a new carbapenem antibiotic, showed negligible neurotoxic effects. The safety and tolerability of intravenous doripenem was evaluated in 1 phase 2 and in 6 phase 3 clinical trials conducted with patients with nosocomial pneumonia, including ventilator-associated pneumonia; complicated intra-abdominal infection; and complicated urinary tract infection. Safety data were available from 1817 patients who received doripenem and 1325 patients who received 1 of 4 active comparator drugs as part of this development program. Overall, intravenous doripenem was found to be safe and well tolerated, demonstrating a safety profile comparable to that of comparator agents and a limited propensity to induce seizures, including when administered via 1-h or 4-h infusion. j.
Insights
Doripenem, a new carbapenem antibiotic, demonstrated favorable safety and tolerability in clinical trials for serious nosocomial infections. This new antibiotic showed a low risk of seizures, comparable to existing treatments.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Trials
Background:
- Carbapenems are crucial for treating severe nosocomial infections.
- Seizures are a primary safety concern with carbapenem antibiotics.
- Doripenem is a novel carbapenem with preclinical evidence of low neurotoxicity.
Purpose of the Study:
- To evaluate the safety and tolerability of intravenous doripenem.
- To compare doripenem's safety profile against active comparator drugs.
- To assess the seizure risk associated with doripenem administration.
Main Methods:
- Phase 2 and 6 Phase 3 clinical trials were conducted.
- Safety data were collected from 1817 patients receiving doripenem.
- 1325 patients received active comparator drugs.
Main Results:
- Intravenous doripenem was found to be safe and well-tolerated.
- Doripenem exhibited a safety profile comparable to comparator agents.
- Doripenem demonstrated a limited propensity to induce seizures, irrespective of infusion duration.
Conclusions:
- Intravenous doripenem is a safe and well-tolerated treatment option for nosocomial infections.
- Doripenem offers a favorable safety profile, including a low risk of seizures.
- Doripenem can be administered via 1-hour or 4-hour infusion without increasing seizure risk.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dosage Interval and Administration Route: Determination Methods
Cardiac Catheterization I: Pre-Procedure Overview
Pharmacokinetics in Pediatric Patients: Drug Excretion